DK1490357T3 - Toluensolvat af darifenacin - Google Patents

Toluensolvat af darifenacin

Info

Publication number
DK1490357T3
DK1490357T3 DK03744716.6T DK03744716T DK1490357T3 DK 1490357 T3 DK1490357 T3 DK 1490357T3 DK 03744716 T DK03744716 T DK 03744716T DK 1490357 T3 DK1490357 T3 DK 1490357T3
Authority
DK
Denmark
Prior art keywords
darifenacin
toluene solvate
solvate
toluene
Prior art date
Application number
DK03744716.6T
Other languages
Danish (da)
English (en)
Inventor
Peter James Dunn
John George Matthews
Trevor Jack Newbury
Garry O'oconnor
Original Assignee
Novartis Int Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9933731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1490357(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Int Pharm Ltd filed Critical Novartis Int Pharm Ltd
Application granted granted Critical
Publication of DK1490357T3 publication Critical patent/DK1490357T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK03744716.6T 2002-03-26 2003-03-17 Toluensolvat af darifenacin DK1490357T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0207104.1A GB0207104D0 (en) 2002-03-26 2002-03-26 Stable hydrate of a muscarinic receptor antagonist
PCT/IB2003/001043 WO2003080599A1 (en) 2002-03-26 2003-03-17 Stable hydrate of a muscarinic receptor antagonist

Publications (1)

Publication Number Publication Date
DK1490357T3 true DK1490357T3 (da) 2011-04-04

Family

ID=9933731

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03744716.6T DK1490357T3 (da) 2002-03-26 2003-03-17 Toluensolvat af darifenacin
DK10177716.7T DK2336124T3 (da) 2002-03-26 2003-03-17 Stabilt hydrat af en muscarinreceptorantagonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10177716.7T DK2336124T3 (da) 2002-03-26 2003-03-17 Stabilt hydrat af en muscarinreceptorantagonist

Country Status (22)

Country Link
US (3) US6930188B2 (enExample)
EP (2) EP2336124B1 (enExample)
JP (2) JP2005524678A (enExample)
KR (4) KR101212908B1 (enExample)
CN (1) CN100345840C (enExample)
AR (1) AR042608A1 (enExample)
AT (1) ATE495169T1 (enExample)
AU (1) AU2003209921A1 (enExample)
BR (2) BRPI0308706B8 (enExample)
CA (1) CA2480287C (enExample)
CY (2) CY1111200T1 (enExample)
DE (1) DE60335711D1 (enExample)
DK (2) DK1490357T3 (enExample)
ES (2) ES2394067T3 (enExample)
GB (1) GB0207104D0 (enExample)
PA (1) PA8569701A1 (enExample)
PT (2) PT2336124E (enExample)
SI (2) SI1490357T1 (enExample)
SV (1) SV2003001515A (enExample)
TW (1) TW200306816A (enExample)
UY (1) UY27735A1 (enExample)
WO (1) WO2003080599A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
US20060258712A1 (en) * 2005-04-24 2006-11-16 Wyeth Methods for modulating bladder function
EP1891034A2 (en) * 2005-12-27 2008-02-27 Teva Pharmaceutical Fine Chemicals S.R.L. Processes for preparing darifenacin hydrobromide
EP2109601A2 (en) * 2007-01-05 2009-10-21 Dr. Reddy's Laboratories Ltd. Preparation of darifenacin and its salts
RU2452728C2 (ru) * 2007-02-23 2012-06-10 Тереванс, Инк. Четвертичные аммониевые дифенилметилсоединения, применимые в качестве антагонистов мускариновых рецепторов
US20090005309A1 (en) * 2007-05-18 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted piperidines
US20100204296A1 (en) * 2007-06-08 2010-08-12 Actavis Group Ptc Ehf Novel Polymorphs of Darifenacin Free Base and its Hydrobromide Salt
WO2009006413A1 (en) * 2007-06-30 2009-01-08 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
AR068322A1 (es) * 2007-07-13 2009-11-11 Medichem Sa Forma amorfa de hidrobromuro de darifenacina y procedimientos para su preparacion
CZ300895B6 (cs) 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
WO2009125426A2 (en) * 2008-02-08 2009-10-15 Neuland Laboratories Ltd NOVEL PROCESS FOR THE PREPARATION OF (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYLϊETHYL]-α.α -DIPHENYL-3-PYRROLIDINEACETAMIDE HYDROBROMIDE
EP2261205A4 (en) 2008-04-02 2012-06-06 Kaneka Corp PROCESS FOR PRODUCING (S) -3- (1-CYANO-1,1-DIPHENYLMETHYL) -PYRROLIDINE
US20110144354A1 (en) * 2008-09-22 2011-06-16 Watson Pharma Private Limited Process for Preparation of Darifenacin and Intermediates Used in the Process
EP2236509A1 (en) 2009-04-01 2010-10-06 Ragactives, S.L. Method for obtaining 1,3-difunctionalized pyrrolidine derivatives
WO2011070419A1 (en) 2009-12-10 2011-06-16 Aurobindo Pharma Limited An improved process for the preparation of darifenacin hydrobromide
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2017106175A2 (en) * 2015-12-14 2017-06-22 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION
CN109641822B (zh) * 2016-08-12 2022-03-11 拜耳作物科学股份公司 制备取代苯乙烯衍生物的方法
CN111278503B (zh) * 2017-09-12 2023-12-05 Lts勒曼治疗系统股份公司 离子电渗微针装置

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9400600D0 (en) 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
JP2001502302A (ja) * 1996-09-19 2001-02-20 アメリカン・ホーム・プロダクツ・コーポレイション 尿失禁を治療する方法
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist

Also Published As

Publication number Publication date
US6930188B2 (en) 2005-08-16
US20080167367A1 (en) 2008-07-10
GB0207104D0 (en) 2002-05-08
EP1490357A1 (en) 2004-12-29
KR20120098888A (ko) 2012-09-05
JP2005524678A (ja) 2005-08-18
CA2480287A1 (en) 2003-10-02
BRPI0308706B1 (pt) 2018-07-10
US7696357B2 (en) 2010-04-13
PA8569701A1 (es) 2003-12-10
DE60335711D1 (de) 2011-02-24
KR20100101182A (ko) 2010-09-16
SI1490357T1 (sl) 2011-05-31
EP1490357B1 (en) 2011-01-12
US20030191176A1 (en) 2003-10-09
WO2003080599A1 (en) 2003-10-02
TW200306816A (en) 2003-12-01
CN1642945A (zh) 2005-07-20
ES2358644T3 (es) 2011-05-12
EP2336124A1 (en) 2011-06-22
SI2336124T1 (sl) 2012-12-31
HK1156626A1 (en) 2012-06-15
BR0308706A (pt) 2005-01-04
BR122018000397B8 (pt) 2021-07-27
KR101026283B1 (ko) 2011-03-31
CN100345840C (zh) 2007-10-31
SV2003001515A (es) 2003-12-15
KR20040093477A (ko) 2004-11-05
DK2336124T3 (da) 2012-12-17
KR101212908B1 (ko) 2012-12-14
BR122018000397B1 (pt) 2019-07-02
PT1490357E (pt) 2011-03-01
UY27735A1 (es) 2003-10-31
PT2336124E (pt) 2012-12-12
CY1113433T1 (el) 2016-06-22
EP2336124B1 (en) 2012-08-29
BRPI0308706B8 (pt) 2021-05-25
ATE495169T1 (de) 2011-01-15
ES2394067T3 (es) 2013-01-16
HK1080847A1 (zh) 2006-05-04
JP2010195828A (ja) 2010-09-09
CY1111200T1 (el) 2015-06-11
AR042608A1 (es) 2005-06-29
US20050245597A1 (en) 2005-11-03
AU2003209921A1 (en) 2003-10-08
KR20110130539A (ko) 2011-12-05
CA2480287C (en) 2011-05-31

Similar Documents

Publication Publication Date Title
DK1490357T3 (da) Toluensolvat af darifenacin
DK1532474T3 (da) Markering af rørforforbindelser
DK1438306T3 (da) Derivater af UK-2A
DE60321740D1 (de) Toner
FI113616B (fi) Instrumentti
DE60306080D1 (de) Toner
NO20043696L (no) Gamma-sekretaseinhibitorer
ITMI20041123A1 (it) Fissaggio
EP1404928A4 (en) STRUCTURE
DK1470732T3 (da) Fremskaffelse af lokaliseringsinformation
IS8283A (is) Umbrotsefni kvetíapíns
DE60336882D1 (de) Toner
DK1625153T3 (da) Acylerede nonadepsipeptider af typen Lysobactin
DE50200230D1 (de) Tripodegelenk
DE60321615D1 (de) Toner
FR2841960B1 (fr) Bague de traversee de cloison
NO20043664L (no) Ny fremgangsmate
DE50200210D1 (de) Tripodegelenk
ATA5212002A (de) Teleskop
DK1472412T3 (da) Byggesæt af brosten
DE60310507D1 (de) Zoomobjektiv
ITMI20021327A1 (it) Nuove ossialchilpiperazine
DE60201909D1 (de) Zoom-verfahren
DK1592417T3 (da) Kombinationen af antidiabetiske lægemidler
FIU20020171U0 (fi) Puupalkki